(Q46455776)

22 December 2017

title

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland (English)

1 reference

22 December 2017

0 references

Lacey LA

1

1 reference

22 December 2017

Wolf A

2

1 reference

22 December 2017

O'shea D

3

1 reference

22 December 2017

Erny S

4

1 reference

22 December 2017

Ruof J

5

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

22 December 2017

International Journal of Obesity

published in

1 reference

22 December 2017

volume

29

1 reference

22 December 2017

issue

8

1 reference

22 December 2017

page(s)

975-982

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.ijo.0802947

exact match

0 references

cites work

Differentiated long-term effects of intentional weight loss on diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Weight gain as a risk factor for clinical diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Current estimates of the economic cost of obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Quality of life in relation to overweight and body fat distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Impairment of health and quality of life using new US federal guidelines for the identification of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Estimating the effect of changes in body mass index on health state preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

The cost of obesity: the Australian perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

A prospective study of obesity and risk of coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

7 January 2021

Obesity morbidity and health care costs in France: an analysis of the 1991–1992 Medical Care Household Survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

7 January 2021

Health care costs of obesity in New Zealand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

7 January 2021

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

7 January 2021

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

7 January 2021

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802947

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.0802947

1 reference

22 December 2017

1 reference

22 December 2017